Cargando…
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Pediatric high-grade gliomas, specifically diffuse midline gliomas, account for only 20% of clinical cases but are 100% fatal. A majority of the DMG cases are characterized by the signature K27M mutation in histone H3. The H3K27M mutation opposes the function of enhancer of zeste homolog 2 (EZH2), t...
Autores principales: | Dhar, Swati, Gadd, Samantha, Patel, Priyam, Vaynshteyn, Jake, Raju, G. Praveen, Hashizume, Rintaro, Brat, Daniel J., Becher, Oren J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994223/ https://www.ncbi.nlm.nih.gov/pubmed/35395831 http://dx.doi.org/10.1186/s40478-022-01336-5 |
Ejemplares similares
-
DIPG-44. A GAIN OF FUNCTION Ezh2 MUTATION DELAYS DIFFUSE INTRINSIC PONTINE GLIOMA PROGRESSION
por: Dhar, Swati, et al.
Publicado: (2020) -
ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma
por: Sasaki, Takahiro, et al.
Publicado: (2020) -
DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020) -
A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell‐of‐origin dependent effects of H3K27M
por: Tomita, Yusuke, et al.
Publicado: (2022) -
Immunotherapy approaches for the treatment of diffuse midline gliomas
por: Bernstock, Joshua D., et al.
Publicado: (2022)